



# CAPA e Newsletter



CHINESE AMERICAN PATHOLOGISTS ASSOCIATION

~ 全美华人病理学会 ~

VOLUME 2 ISSUE 1 2016

## In this issue:

The President's Message 2016	P1
Highlights of the 14th CAPA Annual Meeting (2016)	P2-P5
Highlights of the Second China-US Pathology Symposium (2016)	P4, P6
Introducing CAPA Pathologists/Scientists	P7
Announcements of 2016-2017 Major CAPA Educational Events	P7-P8
CAPA News	P8
Visiting physician/scientist/postdoc positions available at MDACC	P8
Recent Achievements from CAPA Members	P9-P10
Acknowledgements and Advertisements for CAPA Sponsors	P10-P11

### Editing Team:

Huan-You Wang  
 Jun Zhang  
 Fan Chen  
 Jie Song  
 Zenggang Pan  
 Kar-Ming Fung  
 Longwen Chen  
 Yajue Huang  
 Huimiao Jiang

### Design:

Fan Chen



## The President's Message 2016

**D**ear Friends,

It is my distinguished honor and privilege to be elected as the president of the Chinese American Pathologists Association (CAPA) for 2016-2017. Thank you for your support and trust!

CAPA has become an internationally recognized organization within the pathology community, thanks to the strong leadership and strategic visions of our past presidents; dedication from our current and past executive committee members, subcommittee chairs, co-chairs and members; and strong support from our active members.

I would like to express my special thanks to Dr. Fan Lin for his strong leadership and to his leadership team and many active members for their hard work and outstanding contribution to CAPA. We have achieved numerous milestones in CAPA's history in the past year as listed in Dr. Lin's CAPA Annual Report and we had another historic and successful gathering in Seattle. I would like to thank our sponsors, distinguished friends in pathology from China, all CAPA members and friends for your generous support and contribution to the great CAPA community.

As we move into the next year, I look forward to working with our leadership teams and active members to continue the great CAPA programs and to implement new ones as listed below.

1. To organize the First CAPA Companion Meeting at 2016 CAP Annual Meeting in Las Vegas
2. To organize the Second CAPA Diagnostic Pathology Course in Houston
3. To co-organize the Second CAPA-Beijing Pathology Symposium in Beijing

4. To co-organize the Third China-US Pathology Symposium in San Antonio
5. To organize speakers for the 2016 Chinese Society of Pathology Meeting in Hefei (Anhui)
6. To host the 15<sup>th</sup> CAPA Annual Meeting in San Antonio in 2017
7. To foster collaboration with other national and international pathology societies
8. To overhaul and reconstruct CAPA website
9. To publish quarterly CAPA eNewsletter and case of the month
10. To amend the CAPA bylaws
11. To conduct 2017 CAPA election
12. To establish subspecialty subcommittees
13. To recruit new members, validate and organize CAPA membership databases



We are CAPA and we are connected. Together as a team, we will make CAPA a stronger and better organization in the coming years. Again, thank you for your support!

Sincerely yours,

Huamin Wang, MD, PhD

CAPA President, 2016-2017

Professor

The University of Texas M.D. Anderson Cancer Center

Houston, TX

# Highlights of the 14th CAPA Annual Meeting in Seattle, Washington (March 12, 2016) *Photography by Dr. Xiaoping Sun*



Dr. Fan Lin, CAPA President 2015-2016, presenting CAPA Annual Report




Dr. Lizhen Gui, Chair of CAPA Membership Subcommittee, presenting CAPA membership updates



Dr. Jinsong Liu and Dr. Hanlin Wang received the CAPA/ACD Distinguished Pathologist Award presented by Dr. Fan Lin and Dr. Rob Monroe, CMO of ACD



Dr. Richard Friedburg, CAP President, addressing CAPA members and calling for possible collaborations



Dr. Fan Lin presenting the CAPA Honorary Award to Dr. Philip Cagle



Dr. Zu-Hua Gao, CAPA President 2012-2013, presenting CAPA/Zu-Hua Gao Service Award to Dr. Marilyn Bui



Dr. David B. Kaminsky, Executive Vice-President, USCAP, addressing CAPA members and calling for possible collaborations between USCAP and CAPA



Dr. Eric Chen, Dr. Lizhen Gui, Dr. Huihong Xu, Dr. Lanjing Zhang received the CAPA Member of the Year Award presented by Dr. Fan Lin. The other two winners of the CAPA Member of the Year, Dr. Fan Chen and Dr. Ruoqing Huang, was not able to attend the meeting. We thank all of them for their outstanding services and contributions to CAPA.



Dr. Eric Chen, CAPA Treasurer, presenting CAPA finance report

*(Cont'd on Page 3)*

## Highlights of the 14th CAPA Annual Meeting in Seattle, Washington (March 12, 2016) *Photography by Dr. Xiaoping Sun*

*(Cont'd from Page 2)*



CAPA/Gopath Best Abstract Award winners (First Place: Dr. Wei Wang; Second Place: Drs. Hongyan Dai and Qingqing Liu; Third Place: Drs. Jinhua Piao, Wendi Zhou and Bing Ren) with Dr. Hanlin Wang, Chair of CAPA Nomination and Award Committee and Dr. Wei Xin representing Gopath, the sponsor of this award.

CAPA/Motic Best Abstract Award winners (First Place: Dr. Huanwen Wu represented by Dr. Zhiyong Liang; Second Place: Drs. Shi-Xun Lu and Lin Fang represented by Dr. Xiaoli Feng; Third Place: Drs. Liyan Xue, Baowen Zheng and Yan Song) with Dr. Guoping Cai, Co-Chair of CAPA Nomination and Award Committee and Dr. Chen Zhou representing Motic, the sponsor of this award.



*(Cont'd on Page 4)*

## Highlights of the 14th CAPA Annual Meeting in Seattle, Washington (March 12, 2016) *Photography by Dr. Xiaoping Sun*

(Cont'd from Page 3)



Dr. Chin-Lee Wu (first right), the first president of Hua Tuo Society of Pathology (current CAPA) presenting the recognition plaques to past CAPA presidents: Dr. Shu-Yuan Xiao (CAPA President 2008-2009, absent), Dr. Shuan Li (CAPA President 2009-2010, absent), Ming Zhou (CAPA President 2010-2011, absent), Dr. Steven Shen (CAPA President 2011-2012, third right), Zu-Hua Gao (CAPA President 2012-2013, fourth right) and Dr. Jinsong Liu (CAPA President 2013-2014, second right) and Jim Zhai (CAPA President, 2014-2015, absent).



Dr. Huamin Wang, CAPA President 2016-2017, presenting the plaque to Dr. Fan Lin, CAPA President 2015-2016 to thank him for his outstanding leadership and contributions to CAPA.



Dr. Huamin Wang, CAPA President 2016-2017, presenting the look forward for CAPA 2016-2017

## Highlights of the Second China-US Pathology Symposium in Seattle, Washington

**T**he Chinese Society of Pathology (CSP) and CAPA jointly hosted the Second China-US Pathology Symposium on March 12, 2016. The program was led by Drs. Xiu-Wu Bian and Fan Lin, co-organized by Drs. Zhiyong Liang and Lanjing Zhang, and advised by Drs. Minghua Zhu, Jie Chen, Jinsong Liu and Huamin Wang. Approximately 70 pathologists from China and United States attended the meeting. The program included four hot-topic lectures presented by Drs. Zhiyong Liang, Marilyn Bui, Jian Wang and Chin-Lee Wu and six Case Discussions presented by Drs. Huaiyin Shi, Hanlin Wang, Jianhua Zhou, He Wang, Jing Zeng and Xinmin Zhang. This meeting provided a unique platform for the pathologists from China and CAPA to exchange ideas not only in pathology practice, but also in research programs. Given the great success of the first and second symposia, CAPA and CSP will organize the Third China-US Pathology Symposium on Saturday, March 4, 2017 in San Antonio, TX, USA. The conference will be free to all CAPA members. More details will be disclosed when available (Photography by Dr. Huamin Wang).



Dr. Ming-Hua Zhu representing the Chinese Society of Pathology delivering the welcoming message and opening remarks from Dr. Xiu-Wu Bian at the opening ceremony

(Cont'd on Page 6)

# Highlights of the 14th CAPA Annual Meeting in Seattle, Washington (March 12, 2016) *Photography by Dr. Xiaoping Sun*

*(Cont'd from Page 4)*



Left: Our volunteers at the registration desk for CAPA Annual Meeting



Right: CAPA Annual Dinner Party and Karaoke



Group photo at the CAPA Annual Dinner

# Highlights of the Second China-US Pathology Symposium in Seattle, Washington

(Cont'd from Page 4)



Dr. Fan Lin, CAPA President 2015-2016, delivering a welcome speech at the opening ceremony



Dr. Xiang Du from Fudan University Cancer Center and Dr. Huamin Wang, CAPA President 2016-2017, chairing the Hot Topic Section



Dr. Wencai Li from Zhengzhou University Affiliated First Hospital and Dr. Lanjing Zhang chairing the Case Discussion Section with Dr. He Wang presenting an interesting pulmonary case



Dr. Zhiyong Liang from Peking Union Medical College and Dr. Lanjing Zhang, Chair of CAPA Education Committee, co-chairing the conference

Right: Questions from Dr. Jian Wang (Fudan University Cancer Center)



Right: Meeting room filled with pathologists from China and USA at the Second China-US Pathology Symposium



## Introducing CAPA Pathologists/Scientists




Dr. Chen Liu is the Professor and Chairman of the Departments of Pathology and Laboratory Medicine at the Rutgers Robert Wood Johnson Medical School and Rutgers New Jersey Medical School. He is also a Chancellor scholar and the Director of the Liver Pathology Section.

Dr. Liu received his medical degree in China and his Ph.D. degree from the University of Pennsylvania in 1993. He did his postdoctoral training at the Scripps Research Institute in California and pathology residency training at the Medical College of Pennsylvania (Drexel University). Dr. Liu then received his oncological pathology fellowship training at the University of Texas MD Anderson Cancer Center. He was recruited to the University of Florida as an Assistant Professor in 2000. Dr. Liu has developed both the research and clinical programs and obtained the rank of full tenured professor, and vice chair of the Department of Pathology, Immunology, and Laboratory Medicine.

Dr. Liu is an internationally renowned board-certified GI/liver pathologist and an NIH-funded liver disease investigator. As a physician scientist, he is an expert in viral hepatitis, liver cancer, graft-versus-host disease and cancer epigenetics. His research team has made significant contributions to the understanding of virus or alcohol-induced carcinogenesis, cancer metastasis, cancer biomarker discovery and novel therapies using small molecules and immunotherapy. One of the current research programs is to study cancer pathology in real-time and develop precision cancer therapy using individual patient cancer biosystem pioneered by his group. His research work has been continuously funded by NIH and other funding agencies. Dr. Liu has published more than 210 peer-reviewed articles and book chapters and has 5 patents and pending applications. As a well-recognized GI/liver pathologist, he provides large numbers of expert consultations for many physicians/patients throughout the state of Florida and across the US.

As an educator, he has mentored many trainees who are holding academic positions in institutions around the world. He teaches medical students and clinical fellows. He contributed chapters on digestive system and liver pathology in the widely used pathology textbook: Robbin and Cotran's Pathological Basis of Disease. Dr. Liu has given lectures at many regional, state, national and international conferences and Universities. Dr. Liu is also an associate editor for Laboratory Investigation. He is active in a number of committees of national or international organizations. Dr. Liu has been an active member of NIH study groups since 2003 and is currently a permanent member of NIH Clinical Oncology Study Section. Dr. Liu received several prestigious awards including UF Research Foundation Professorship, Innovator Award, Howard Hughes Undergraduate Mentor Awards, NIH Midcareer Mentor Award, and American Liver Foundation Liver Research Scholar award.



Dr. Jiaoti Huang earned his medical degree from Anhui Medical University in 1983 and a Master's degree in Pharmacology from the Institute of Radiation Medicine in Beijing in 1986. He earned his PhD from New York University School of Medicine (1987-1990). He was a Leukemia Society of America Postdoctoral Fellow at NYU and Yale University. He did residency training in pathology at NYU School of Medicine and a fellowship in Oncologic Surgical Pathology at Memorial Sloan-Kettering Cancer Center. He became an assistant professor at the University of Rochester in July 2000 and rose to the rank of full professor in 2007. Dr. Huang moved to UCLA in 2008 and came to Duke University at the beginning of 2016. He is currently Chair of Department of Pathology at Duke University.

Dr. Huang is an internationally well-known surgical pathologist and prostate cancer researcher. His clinical expertise is in the pathologic diagnosis of genitourinary tumors. His research laboratory investigates the molecular mechanisms, biomarkers, imaging and novel therapies for advanced prostate cancer. His research laboratory is a leader in studying neuroendocrine differentiation of prostate cancer and molecular pathogenesis of prostatic small cell neuroendocrine carcinoma. Dr. Huang has published close to 200 research papers, review articles and book chapters. Among his many scientific contributions, he recently discovered a signaling pathway that keeps neuroendocrine cells of prostate adenocarcinoma in a quiescent state, and a molecular mechanism for disease progression to small cell neuroendocrine carcinoma. His research has been supported by the National Institutes of Health, Department of Defense Prostate Cancer Research Program, Prostate Cancer Foundation, and a Stand Up to Cancer Dream Team award. He is currently the principle investigator of two NIH RO1 grant, and one DOD grant as well as co-PI of several other grants.

### Announcements of 2016-2017 Major CAPA Educational Events

- Pitfalls and Pearls in Diagnostic Pathology Second CAPA Diagnostic Pathology Course**  
Saturday, November 12 – Sunday, November 13, 2016  
University of Texas MD Anderson Cancer Center, Houston, Texas  
To register, please copy the link below to a browser.  
<https://docs.google.com/forms/d/10uCv1p37C1m7mOMYya3IRVeuaffmLNmGfMlhdEmZAM/viewform>  
Please visit [capaht.org](http://capaht.org) for more information

(Cont'd on Page 8)

## Announcements of 2016-2017 Major CAPA Educational Events

(Cont'd from Page 7)

2. **Frontiers of Diagnostic Pathology  
First CAPA Companion Meeting at CAP 2016  
Annual Meeting**  
5:30 – 7:30 pm, Saturday September 24, 2016  
Wynn Encore, Las Vegas, Nevada
3. **Updates on Molecular and Neoplastic  
Pathology  
Second CAPA-Beijing Pathology Summit**  
September 3-4, 2016  
Beijing, China
4. **Third China-US Pathology Symposium**  
March 4, 2017  
San Antonio, Texas
5. **CAPA will organize two sections on the  
Molecular Pathology of Solid Tumors at the  
10<sup>th</sup> Asia Pacific International Academy of  
Pathology (APIAP) Congress**  
April 24<sup>th</sup> - 27<sup>th</sup>, 2017  
Bali, Indonesia

## CAPA News

1. CAPA has successfully passed the proposed changes in CAPA Bylaw at the 14<sup>th</sup> CAPA Annual Meeting in Seattle, Washington. The major proposed changes include the qualification and rights for different categories of CAPA membership; CAPA elections; eligibility, term and duties for all CAPA offices; and added the disclosure statement for the tax exemption status of CAPA. Please visit [www.capaht.org](http://www.capaht.org), click on Bylaws icon to review the updated version of CAPA Bylaw.
2. CAPA sponsored the First Hematopathology Case Presentation Conference on March 14, 2016 in Seattle, Washington. This meeting was organized by Dr. Henry Dong, Jerald Gong, Zenggang Pan, Huan-You Wang, Linsheng Zhang, and Jiehao Zhou and well received by the audience.
3. CAPA is a non-financial sponsor for the Cancer Biomarkers Conference II (CBCII), which will take place on September 10 and 11, 2016 at the Houston Methodist Research Institute, Houston, Texas.
4. CAPA is sponsoring the Chinese Society of Pathology (CSP) Annual Meeting, which will take place in Hefei, Anhui Province, November 25-27, 2016

## Visiting physician/scientist/postdoc positions available at MD Anderson Cancer Center

Visiting physician/scholar/scientist/postdoc positions are available for motivated hematologists or hematopathologists to join an active group at the University of Texas MD Anderson Cancer Center. Our major interest is: risk stratification of chronic myeloid leukemia, Ph-negative myeloproliferative neoplasm, plasma cell myeloma and diffuse large B-cell lymphoma based on cytogenetic profiles and other biomarkers. However, we are open to any areas of neoplastic hematology.

The visiting physician/scholar/scientist/postdoc are expected to finish several half-ready projects based on established databases in one or two of these diseases leading to rapid publications in highly-regarded journals in hematology and pathology. They can also develop projects based on their own interest. They will dedicate about two-third of their time to data analysis and manuscript writing, and one third to data collection. No bench experiment is required. Any additional experiment/tests will be done by other support staff or research core facilities. Both senior hematologists/pathologists, experienced fellows, residents, or PhD students in their late stage of graduate studies will be considered. This is an ideal opportunity for the experienced physicians to polish their CV, and once in a blue moon opportunity for the young physicians to quickly jump-start their career growth. Please be noted that this is a non-paid position. However, they might be compensated in some ways later depending on contribution.

The fast-paced publishing requires tremendous amount of effort and dedication as well as excellent written English skills. Background in hematology or hematopathology and 1st-author publications in English journals are expected. Knowledge of cytogenetics will be extremely helpful.

Recent work can be found in: *Blood*. 2016 Mar 22. pii: blood-2016-01-690230, *Leukemia*. 2016 Feb 3. doi: 10.1038/leu.2016.6, *Leukemia*. 2015 Nov;29(11):2263-6, *Blood*. 2015 Oct 1;126(14):1699-706, *Blood* 2015 Apr 30; 125:2875. *Blood*. 2013 May 16;121(20):4021-31, *Blood*. 2013 Apr 4;121(4):2715-24.

MD Anderson is one of the largest cancer centers in the world. We have about 20,000 employees, 6,000-7,000 clinical and research trainees, observers and visitors, and about 1,100 volunteers. We have been ranked as the top cancer hospital for 12 of the past 15 years, and one of the top two cancer hospitals every year since U.S. News & World Report began its annual "America's Best Hospitals" survey in 1990. Our doctors treat more rare cancers in a single day than most physicians see in a lifetime.

Contact: Shimin Hu, MD, PhD, [shu1@mdanderson.org](mailto:shu1@mdanderson.org)



## Recent Achievements from CAPA Members

### GRANTS, HONORS AND AWARDS IN 2016

1. **Dr. Huamin Wang** received his five-year RO1 funding from NIH/NCI on novel signaling pathways regulating pancreatic cancer pathogenesis starting April 1, 2016
2. 2016 **AGT Student Research Award**, AGT 41<sup>st</sup> Annual Meeting, June 23-25, 2016, Orange County, CA (Graduate student: **Kristina Regmi**, for MYC rearrangement in plasma cell myeloma)
3. **CAPA/GoPath Best Abstract Award, 1<sup>st</sup> Place**, USCAP-2016, March 12-18, 2016, Seattle, WA (Fellow: **Wei Wang**, for Risk Stratification of CML)
4. **Platform Competition-1st Place**, Texas Society of Pathologists, Jan 17, 2016, Dallas, TX (Fellow: **Wei Wang**, for Risk Stratification of CML)

### PEER-REVIEW PUBLICATIONS IN 2016

1. Wang W, Cortes JE, Tang G, Khoury JD, Wang S, Bueso-Ramos CE, DiGiuseppe JA, Chen Z, Kantarjian KM, Medeiros LJ, **Hu S**. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. *Blood*. 2016 Mar 22. pii: blood-2016-01-690230
2. Chen Z, Cortes JE, Jorgensen JL, Wang W, Yin CC, You MJ, Jabbour E, Kantarjian H, Medeiros LJ, **Hu S**. Different impact of additional cytogenetic abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. *Leukemia*. 2016 Feb 3. doi: 10.1038/leu.2016.6. [Epub ahead of print]
3. Chen Z, **Hu S**. *MYC/BCL2* double-hit lymphoma mimicking acute leukemia at initial presentation. *Blood*. 2016 Feb 25;127(8):1072. doi: 10.1182/blood-2015-11-683730
4. Chen Z, Wang W, Cortes JE, Liu E, Miranda RN, Zhao C, Yuan J, Lu, X, Yang W, Dadfarnia M, Kantarjian HM, Medeiros LJ, **Hu S**. Differential clinical and prognostic impact of myeloid sarcoma versus medullary myeloid blast phase in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. *Blood Cancer Journal* (in press)
5. Wang W, Ali S, Tang Z, Miranda RN, Medeiros LJ, **Hu S**. Constitutional pericentric inversion of chromosome 9 has no impact on survival in chronic myelogenous leukemia. *Ann Hematol* 2016 Mar;95(4):657-9. doi: 10.1007/s00277-016-2592-3. Epub 2016 Jan 13.
6. Li Y, **Hu S**, Wang SA, Li S, Huh YO, Tang Z, Medeiros LJ, Tang G. The clinical significance of 8q245/MYC rearrangement in chronic lymphocytic leukemia. *Mod Pathol*. 2016 Feb 26. doi: 10.1038/modpathol.2016.35. [Epub ahead of print]
7. Goswami RS, Wang SA, Tang Z, Li Y, Zuo W, **Hu S**, Li S, Medeiros LJ, Tang G. Newly emerged isolated del(7q) in patients with prior cytotoxic therapies may not always be associated with therapy-related myeloid neoplasm. *Mod Pathol*. 2016 Apr 8. Doi: 10.1038/modpath. 2016.67. [Epub ahead of print]
8. Li S, Weiss VL, Wang XJ, Desai PA, **Hu S**, Yin CC, Tang G, Reddy NM, Medeiros LJ, Lin P. High-grade B-cell lymphoma with MYC rearrangement and without BCL2 and BCL6 rearrangements is associated with high TP53 expression and a poor prognosis. *Am J Surg Pathol*. 2016 Feb;40(2):253-61. doi: 10.1097/PAS.0000000000000542.
9. Ye Q, Xu-Monette ZY, Tzankov A, Deng L, Wang X, Manyam GC, Visco C, Montes-Moreno S, Zhang L, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WWL, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Parsons BM, Møller MB, Piris MA, Winter JN, Medeiros LJ, **Hu S**, Young KH. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. *Oncotarget*. 2016 Jan 19;7(3):2401-16. doi: 10.18632/oncotarget.6262.
10. Yabe M, Medeiros LJ, Tang G, Wang SA, Ahmed S, Nieto Y, **Hu S**, Bhagat G, Oki Y, Patel KP, Routbort M, Luthra R, Fanale MA, Bueso-Ramos CE, Jorgensen JL, Vega F, Chen W, Hoehn D, Konoplev S, Milton DR, Bassett R, Wistuba I, Li S, You MJ, Young KH, Miranda RN. Prognostic factors of hepatosplenic T-cell lymphoma: clinicopathologic study of 28 cases. *Am J Surg Pathol*. 2016 May;40(5):676-88. Doi: 10.1097/PAS.0000000000000614

(Cont'd on Page 10)

# Recent Achievements from CAPA Members

(Cont'd from Page 9)

## BOOKS IN 2016

1. **Qihui “Jim” Zhai, Jae Y. Ro:** Advances in Surgical pathology: BLADDER CANCER. *Series Editors* Philip T. Cagle and Timothy C. Allen
2. **Yun Gong:** Metastatic Neoplasms in Fine-Needle Aspiration Cytology: Diagnostic Tips and Traps. ISBN 978-3-319-23621-6

## LESSONS AND COURSES:

**Ming Zhou :**

USCAP short course

1. High Yield Urological Pathology: Common and Important Diagnoses Not to be Missed in Daily Practice. United States and Canadian Academy of Pathology Annual Meeting, Boston, MA (2014-2016)
2. Diagnosis of Renal Neoplasms Using Integrated Histologic, Cytologic and Molecular Approaches in the Era of Precision Medicine. United States and Canadian Academy of Pathology Annual Meeting (2016)

## CAPA ACKNOWLEDGES THE FOLLOWING SPONSORS FOR THEIR SUPPORT

Advanced Cell Diagnostics, Inc.  
 American Society of Clinical Pathology  
 BioGenex  
 Cell Marque  
 Dian Diagnostics  
 Foundation Medicine  
 Geisinger IHC Reference Lab  
 Gopath  
 Kingmed  
 Maixin  
 Motic  
 NovoDiax, Inc.  
 Roche/Ventana  
 Roche Diagnostics China  
 Rosetta Genomics

Stains are a good thing ...  
 Quality stains are our thing

Geisinger

Please stop by and see  
 Geisinger IHC at the USCAP  
 2016 Annual Meeting in Seattle  
 from March 14 – 16 at booth #538.

geisingerihc.com

**MXB**  
 biotechnologies

Maixin provides comprehensive range of  
 solutions for immunohistochemistry

**Biotechnologies**  
 福州迈新生物技术开发有限公司  
 ☎ : 400-8889-853/010-8891-156

**10 MINUTE**  
**DIRECT IHC** **INTRAOPERATIVE**

Time In Minute	Procedure
0-5	Fixation
0-1	Wash in PBS
0	No Blocking
5	PolyHRP-Antibody
0-4	Wash in Water
1	DAB
0-1	Wash in Water
2-3	Counter Staining + Dehydration + Coverslipping
<b>9-10</b>	<b>Total Time</b>

**Available Products:**

- ihcDirect AE1/AE3
- ihcDirect Mart-1
- ihcDirect CK8/18
- ihcDirect Synaptophysin
- ihcDirect Herceptin

**NOVODIAX**

VISIT [www.novodiox.com](http://www.novodiox.com)  
 CALL 1.888.439.2716  
 EMAIL [novoinfo@novodiox.com](mailto:novoinfo@novodiox.com)

# CAPA ACKNOWLEDGES THE FOLLOWING SPONSORS FOR THEIR SUPPORT

**No antibody.  
No problem.**

Breakthrough multiplex RNA *in situ* hybridization for any gene with RNAscope® technology.

Because up to 76% of protein-coding genes have no reliable antibody for immunohistochemistry (IHC), your research often comes to a screeching halt while you wait for a new antibody to be developed. With rapid probe design and universal assay workflows for any gene, RNAscope® technology frees you from the hassles of antibody screening, saving you precious time and effort, while driving publication quality data.

Learn more about RNAscope® Technology at [www.acdbio.com](http://www.acdbio.com)



**ACD**  
Advanced Cell Diagnostics

For Research Use Only. Not for diagnostic use. RNAscope is a registered trademark of Advanced Cell Diagnostics, Inc. In the United States or other countries. All rights reserved. ©2015 Advanced Cell Diagnostics, Inc.

## Rare for you but not for Foundation Medicine

RARE/UNCOMMON SUBTYPE	PERTINENT TUMOR DRIVER	FDA APPROVED TARGETED THERAPIES	FDA APPROVED THERAPIES IN ANOTHER TUMOR TYPE
Non-Serous Ovarian Cancer, e.g. Ovarian Clear cell	BRCA1/2	Olaparib	Trastuzumab, Pembrolizumab
	BRIP1		Pazopanib, Pazopanib
	FRR1/2/3		Temsirolimus, Everolimus
	AKT1/2		Olaparib and others
Pancreaticobiliary Cancers: Cholangiocarcinoma Pancreas Cysticobiliary	IGH1/2		Azacitidine, Decitabine
	BRIP1		Trastuzumab, Trastuzumab, ADHES
	FGFR2		Pazopanib
	BRCA1		Oestradiol, Trastuzumab, Venetoclax
	PTEN		Everolimus
	BRCA2		Trastuzumab, Pembrolizumab
	ERBB2		Trastuzumab, Pembrolizumab
Uncommon subtypes of breast cancer	CDKN1	Palbocicli	Trastuzumab, Pembrolizumab
	BRCA1/2		Trastuzumab, Pembrolizumab
	ESRR		Abiraterone, Celecoxib
	PKM3, NF1, STK11, ARID1A, PTEN		Erlotinib, Lapatinib, Pembrolizumab, Trastuzumab, Everolimus, Temsirolimus
Salivary Gland	ERBB2		Trastuzumab, Pembrolizumab
	ESRR		Carbimazole, Lapatinib
	PTEN		Temsirolimus, Everolimus
	BRCA1/2		Trastuzumab, Pembrolizumab
	BRCA1		Trastuzumab, Pembrolizumab

Comprehensive genomic profiling using FoundationOne has been performed on > 16,000 uncommon tumor cases. Learn more at: [USCAP Annual Meeting Booth #541](http://USCAP Annual Meeting Booth #541)

**FOUNDATION MEDICINE**

## BioGenex

### Game Changer



Integrated eFISHiency System

- FISH Probes
- Detection Systems
- Smart Automation  
Hands-On Time < 30 min.  
Up to 10 protocols per run

### miRNA In Situ - Dawn of a New Era



For Clinical Research & Tumour Analysis:

- Cancer of Unknown Primary
- Undifferentiated Tumors
- Cancer Staging



**Xmatrix<sup>TM</sup> NANO**

**Xmatrix<sup>TM</sup> ELITE-INFINITY and NANO miRNA-ISH Automation**

Broadest portfolio of FDA-cleared image analysis algorithms with the VENTANA Digital Pathology Solution

■ER ■PR ■HER2 ■Ki-67 ■p53

VENTANA and the VENTANA logo are trademarks of Roche.  
© 2015 Roche Diagnostics Corporation  
9115 Hague Road • PO Box 50414 • Indianapolis, IN 46250



Digital Scanner and Telepathology Platform  
Automated Cervical Cancer Screening  
Cancer DNA Ploidy Analysis  
Cytology and Surgical Pathology Services

美克奥迪(厦门)医疗诊断系统有限公司  
MOTIC (XIAMEN) MEDICAL DIAGNOSTIC SYSTEMS CO., LTD.

厦门美克奥迪医学检验所  
XIAMEN MOTIC MEDICAL LABORATORY

切片扫描  
通知会诊  
数字病理远程会诊平台  
www.moticpathology.com  
上传平台  
出具报告

Motic Medical Diagnostic Systems, Xiamen, China  
[med.motic.com](http://med.motic.com)